A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers.
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2012
At a glance
- Drugs VB 201 (Primary)
- Indications Atherosclerosis
- Focus Biomarker; Pharmacodynamics
- 13 Jun 2012 New source identified and integrated: European Clinical Trials Database record EudraCT2010-020783-38.
- 15 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jun 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.